{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:53:31Z","timestamp":1792205611744,"version":"4.4.0"},"reference-count":114,"publisher":"European Respiratory Society (ERS)","issue":"178","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2025,9,11]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n                      is a common cause of bacterial pneumonia, bacteraemia and meningitis in adults, especially among older adults and individuals with specific underlying medical conditions. The composition of the capsular polysaccharides distinguishes different pneumococcal serotypes and serves as the target for commercially available vaccines. The 20-valent pneumococcal conjugate vaccine (PCV20) was introduced in 2021, conferring protection to seven additional serotypes over PCV13 and five over PCV15, and, thus, providing increased coverage against common serotypes that cause invasive pneumococcal disease (IPD) and community-acquired pneumonia. The present narrative review summarises current recommendations for pneumococcal vaccination in different countries, focusing on adult and at-risk populations, safety, tolerability, and cost-effectiveness.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search of existing literature was conducted on PubMed, Scopus and government websites to gather relevant articles, studies and recommendations about PCV20. The information was summarised to provide an overview.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The recommendations for adults over 65 years of age support the use of a single dose of PCV20, and a single booster of PCV20 for people who had previously received PCV13 or PPSV23. The administration of PCV20 is also recommended for those who have not completed the vaccine schedules for PCV13 or PPSV23. Several countries have recently included PCV20 in the vaccination of adults and children at higher risk of developing IPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The efficacy, safety and cost-effectiveness of PCV20 support its use in preventing invasive and noninvasive pneumococcal disease across age groups, including those with underlying health conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/16000617.0016-2025","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T09:30:14Z","timestamp":1762939814000},"page":"250016","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Recommendations on PCV20 vaccine in adults and at-risk populations"],"prefix":"10.1183","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1600-4474","authenticated-orcid":false,"given":"Giovanni","family":"Sotgiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Puci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bartoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2285-9970","authenticated-orcid":false,"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-4531","authenticated-orcid":false,"given":"Stefano","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"2025111201300703000_34.178.250016.1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3390\/vaccines9050420","article-title":"Pneumonia and invasive pneumococcal diseases: the role of pneumococcal conjugate vaccine in the era of multi-drug resistance","volume":"9","author":"Scelfo","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2025111201300703000_34.178.250016.2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3390\/vaccines11050908","article-title":"Pneumococcal vaccination in adults: a narrative review of considerations for individualized decision-making","volume":"11","author":"See","year":"2023","journal-title":"Vaccines"},{"key":"2025111201300703000_34.178.250016.3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12879-016-1648-2","article-title":"Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors","volume":"16","author":"Backhaus","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2025111201300703000_34.178.250016.4","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-211767"},{"key":"2025111201300703000_34.178.250016.5","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s12879-018-3326-z","article-title":"Clinical and economic burden of pneumococcal disease in US adults aged 19\u201364 years with chronic or immunocompromising diseases: an observational database study","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2025111201300703000_34.178.250016.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-018-0001-8"},{"key":"2025111201300703000_34.178.250016.7","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1093\/infdis\/jiae351","article-title":"Pneumococcal carriage and disease in adults in England 2011\u20132019: the importance of adults as a reservoir for pneumococcus in communities","volume":"231","author":"El Safadi","year":"2025","journal-title":"J Infect Dis"},{"key":"2025111201300703000_34.178.250016.8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.7774\/cevr.2024.13.2.91","article-title":"A narrative review of genomic characteristics, serotype, immunogenicity, and vaccine development of Streptococcus pneumoniae capsular polysaccharide","volume":"13","author":"Sari","year":"2024","journal-title":"Clin Exp Vaccine Res"},{"key":"2025111201300703000_34.178.250016.9","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12188"},{"key":"2025111201300703000_34.178.250016.10","doi-asserted-by":"crossref","first-page":"e0169368","DOI":"10.1371\/journal.pone.0169368","article-title":"Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis","volume":"12","author":"Falkenhorst","year":"2017","journal-title":"PLoS One"},{"key":"2025111201300703000_34.178.250016.11","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3390\/microorganisms11061376","article-title":"Pneumococcal serotype evolution and burden in European adults in the last decade: a systematic review","volume":"11","author":"Teixeira","year":"2023","journal-title":"Microorganisms"},{"key":"2025111201300703000_34.178.250016.12","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7239a5"},{"key":"2025111201300703000_34.178.250016.13","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7203a1"},{"key":"2025111201300703000_34.178.250016.14","first-page":"838","article-title":"Prevalence, clinical severity, and serotype distribution of pneumococcal pneumonia among adults hospitalized with community-acquired pneumonia in Tennessee and Georgia, 2018\u20132022","volume":"79","author":"Self","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025111201300703000_34.178.250016.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75691-5"},{"key":"2025111201300703000_34.178.250016.16","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/cid\/ciab375","article-title":"Expanded analysis of 20 pneumococcal serotypes associated with radiographically confirmed community-acquired pneumonia in hospitalized US adults","volume":"73","author":"Isturiz","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025111201300703000_34.178.250016.17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177113"},{"key":"2025111201300703000_34.178.250016.18","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3390\/microorganisms11071816","article-title":"Systematic literature review of the epidemiological characteristics of pneumococcal disease caused by the additional serotypes covered by the 20-valent pneumococcal conjugate vaccine","volume":"11","author":"M\u00e9roc","year":"2023","journal-title":"Microorganisms"},{"key":"2025111201300703000_34.178.250016.19","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.3390\/microorganisms11112781","article-title":"Pneumococcal serotypes associated with community-acquired pneumonia hospitalizations in adults in Spain, 2016\u20132020: the CAPA study","volume":"11","author":"Men\u00e9ndez","year":"2023","journal-title":"Microorganisms"},{"key":"2025111201300703000_34.178.250016.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00665-0"},{"key":"2025111201300703000_34.178.250016.21","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7104a1"},{"key":"2025111201300703000_34.178.250016.22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab990"},{"key":"2025111201300703000_34.178.250016.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408544"},{"key":"2025111201300703000_34.178.250016.24","doi-asserted-by":"crossref","first-page":"ofaf069","DOI":"10.1093\/ofid\/ofaf069","article-title":"Immunogenicity and safety of the higher-valent pneumococcal conjugate vaccine vs the 13-valent pneumococcal conjugate vaccine in older adults: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Ngamprasertchai","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2025111201300703000_34.178.250016.25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.15585\/mmwr.mm7336a3","article-title":"Use of 21-valent pneumococcal conjugate vaccine among US adults: recommendations of the advisory committee on immunization practices \u2013 United States, 2024","volume":"73","author":"Kobayashi","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025111201300703000_34.178.250016.26","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S1473-3099(24)00344-X","article-title":"Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial","volume":"24","author":"Platt","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025111201300703000_34.178.250016.27","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1093\/cid\/ciae383","article-title":"A phase 3 clinical study to evaluate the safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine-experienced adults 50 years of age or older (STRIDE-6)","volume":"79","author":"Scott","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025111201300703000_34.178.250016.28","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1016\/j.vaccine.2021.03.070","article-title":"Non-clinical immunological comparison of a next-generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23)","volume":"39","author":"Fairman","year":"2021","journal-title":"Vaccine"},{"key":"2025111201300703000_34.178.250016.29","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/phar.2723","article-title":"Pneumococcal vaccination\u2013a literature review and practice guideline update","volume":"42","author":"El-Beyrouty","year":"2022","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"2025111201300703000_34.178.250016.30","doi-asserted-by":"crossref","first-page":"84","DOI":"10.14745\/ccdr.v51i23a03","article-title":"Cost effectiveness of a 21-valent pneumococcal conjugate vaccine in adults: a systematic review of economic evaluations","volume":"51","author":"Simmons","year":"2025","journal-title":"Can Commun Dis Rep"},{"key":"2025111201300703000_34.178.250016.31","doi-asserted-by":"crossref","first-page":"7494","DOI":"10.1016\/j.vaccine.2021.10.032","article-title":"A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults \u226565 years of age with different prior pneumococcal vaccination","volume":"39","author":"Cannon","year":"2021","journal-title":"Vaccine"},{"key":"2025111201300703000_34.178.250016.32","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(07)70210-4"},{"key":"2025111201300703000_34.178.250016.33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cmi.2017.05.016","article-title":"Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients under treatment with chronic haemodialysis: a longitudinal quasi-experimental phase IV study","volume":"24","author":"Vandecasteele","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2025111201300703000_34.178.250016.34","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7401a1"},{"key":"2025111201300703000_34.178.250016.35","unstructured":"Public Health Agency of Canada . Summary of NACI statement of November 15, 2024: Recommendations on the use of pneumococcal vaccines in adults, including PNEU-C-21. Date last accessed: December 2024. www.canada.ca\/en\/public-health\/services\/publications\/vaccines-immunization\/national-advisory-committee-immunization-summary-recommendations-use-pneumococcal-vaccines-adults-pneu-c-21.html."},{"key":"2025111201300703000_34.178.250016.36","unstructured":"European Commission . Union Register of medicinal products for human use: Prevenar 20. Date last accessed: December 2024. https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h1612.htm"},{"key":"2025111201300703000_34.178.250016.37","unstructured":"European Centre for Disease Prevention and Control . Vaccine Scheduler. Pneumococcal disease: recommended vaccinations. Date last accessed: December 2024. https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=25&SelectedCountryIdByDisease=-1"},{"key":"2025111201300703000_34.178.250016.38","unstructured":"Hoge Gezondheidsraad . Vaccinate Tegen Pneumokokken (Volwassenen). Date last accessed: December 2024. www.health.belgium.be\/sites\/default\/files\/uploads\/fields\/fpshealth_theme_file\/20220908_hgr-9674_pneumo_vweb.pdf"},{"key":"2025111201300703000_34.178.250016.39","unstructured":"Robert Koch Institut . Aktualisierung der Empfehlungen der STIKO zur Standardimpfung von Personen \u226560 Jahre sowie zur Indikationsimpfung von Risikogruppen gegen Pneumokokken. Date last accessed: December 2024. https:\/\/edoc.rki.de\/handle\/176904\/11307.2"},{"key":"2025111201300703000_34.178.250016.40","unstructured":"Ministry of Health Greece . National adult immunization program 2023. Date last accessed: December 2024. www.moh.gov.gr\/articles\/health\/dieythynsh-dhmosias-ygieinhs\/emboliasmoi\/ethniko-programma-emboliasmwn-epe-enhlikwn\/11251-ethniko-programma-emboliasmwn-enhlikwn-2023"},{"key":"2025111201300703000_34.178.250016.41","unstructured":"National Center for Public Health . Methodological letter of the National Center for Public Health about the 2022 vaccinations: Hungary. Date last accessed: December 2024. www.antsz.hu\/data\/cms101372\/VML_2022_NNK.pdf"},{"key":"2025111201300703000_34.178.250016.42","unstructured":"R\u012bga Stradi\u0146\u0161 University . Practical recommendations for vaccination for adults and individuals of risk groups in Latvia. Date last accessed: December 2024. https:\/\/science.rsu.lv\/en\/publications\/praktiskas-rekomend%C4%81cijas-vakcin%C4%81cijai-pieaugu%C5%A1ajiem-un-riska-gru-3"},{"key":"2025111201300703000_34.178.250016.43","unstructured":"Conseil Sup\u00e9rieur des Maladies Infectieuses . Luxemburg. Recommandations du Conseil sup\u00e9rieur des maladies infectieuses pour la vaccination contre le pneumocoque pour les populations \u00e0 risque adultes (18 ans et plus) ou \u00e2g\u00e9es de 65 ans et plus. Date last accessed: December 2024. https:\/\/sante.public.lu\/fr\/espace-professionnel\/recommandations\/conseil-maladies-infectieuses\/infection-pneumocoques.html"},{"key":"2025111201300703000_34.178.250016.44","unstructured":"Health Council of the Netherlands . Pneumococcal vaccination of the elderly. Date last accessed: December 2024. www.healthcouncil.nl\/documents\/advisory-reports\/2023\/06\/20\/pneumococcal-vaccination-of-the-elderly-2023"},{"key":"2025111201300703000_34.178.250016.45","unstructured":"Stacje sanitarno-epidemiologiczne . Program Szczepie\u0144 Ochronnych na rok 2023. Date last accessed: December 2024. www.gov.pl\/web\/psse-zyrardow\/program-szczepien-ochronnych-na-rok-2023"},{"key":"2025111201300703000_34.178.250016.46","unstructured":"Monitorul Oficial Al Romaniei . Decisions of the government of Romania. Date last accessed: December 2024. https:\/\/media.hotnews.ro\/media_server1\/document-2023-09-15-26535425-0-monitorul-oficial-partea-832.pdf"},{"key":"2025111201300703000_34.178.250016.47","unstructured":"Monitorul Oficial Al Romaniei . Decision no. 781. Date last accessed: December 2024. https:\/\/legislatie.just.ro\/Public\/DetaliiDocument\/274129"},{"key":"2025111201300703000_34.178.250016.48","unstructured":"Junta de Andaluc\u00eda . Pneumococcus vaccination program in Andalusia 2023. Date last accessed: December 2024. www.andavac.es\/wp-content\/uploads\/2023\/04\/Instruccion-DGSPyOF_6_2023-Vacunacion-Neumococo-Andalucia-Abril-2023-F.pdf"},{"key":"2025111201300703000_34.178.250016.49","unstructured":"Gobierno de Arag\u00f3n . Circular DGSP 02-2024. Actualizaci\u00f3n vacunaci\u00f3n frente a Neumococo. Date last accessed: December 2024. https:\/\/www.aragon.es\/documents\/d\/guest\/circular_dgsp_02-2024_actualizacion_vacunacion_neumococo_2024-def-pdf"},{"key":"2025111201300703000_34.178.250016.50","unstructured":"Junta de Castilla y Le\u00f3n . New vaccination and immunization calendar for life \u2013 Castilla y Le\u00f3n 2024. Date last accessed: December 2024. www.saludcastillayleon.es\/profesionales\/es\/vacunaciones\/nuevo-calendario-vacunaciones-inmunizaciones-toda-vida-cast"},{"key":"2025111201300703000_34.178.250016.51","unstructured":"Departament de Salut Catalunya . Recomanacions de la vacunaci sistem\u00e0tica antipneumoc ccica conjugada 20-valent a Catalunya. Date last accessed: December 2024. https:\/\/salutpublica.gencat.cat\/web\/.content\/minisite\/aspcat\/promocio_salut\/vacunacions\/02protocols_i_recomanacions\/1358_PREVENTIVA_Recomanacions-de-la-vacunacio-sistematica-antipneumococcia-conjugada-20-valent-a-Catalunya-nov-2022.pdf"},{"key":"2025111201300703000_34.178.250016.52","unstructured":"Comunidad de Madrid . Vacunaci\u00f3n frente a neumococo en el adulto. Informaci\u00f3n para profesionales sanitarios. Date last accessed: December 2024. https:\/\/www.comunidad.madrid\/sites\/default\/files\/doc\/sanidad\/prev\/doc_tecnico_vacunacion_frente_a_neumococo_en_el_adulto_def.pdf"},{"key":"2025111201300703000_34.178.250016.53","unstructured":"General Public Health Galicia . Recomendaci\u00f3ns de vacinaci\u00f3n fronte ao pneumococo. Date last accessed: December 2024. https:\/\/www.sergas.es\/Saude-publica\/Vacinaci%C3%B3n-fronte-ao-pneumococo?idioma=es"},{"key":"2025111201300703000_34.178.250016.54","unstructured":"Portal Sanitario de la Regi\u00f3n de Murcia . Orden de 23 de febrero de 2023, de la Consejer\u00eda de Salud relativa al calendario de vacunaci\u00f3n 2023 para todas las edades de la vida de la Comunidad Aut\u00f3noma de la Regi\u00f3n de Murcia, as\u00ed como para grupos y situaciones de riesgo y para situaciones especiales. Date last accessed: December 2024. www.murciasalud.es\/en\/-\/borm-2023-1450"},{"key":"2025111201300703000_34.178.250016.55","unstructured":"Salud y Pol\u00edticas Sociales . Actualizaci\u00f3n en vacunaci\u00f3n frente al neumococo. Date last accessed: December 2024. www.riojasalud.es\/files\/content\/salud-publica-consumo\/epidemiologia\/vacunaciones\/Actualizacion_neumococo.pdf"},{"key":"2025111201300703000_34.178.250016.56","unstructured":"Bundesministerium f\u00fcr Soziales, Gesundheit, Pflege und Konsumentenschutz (BMSGPK) . Impfplan \u00d6sterreich 2024\/2025. Version 1.0 vom 1.10.2024. Date last accessed: December 2024. https:\/\/reisemed.at\/wp-content\/uploads\/Impfplan-Oesterreich-2024-2025.pdf"},{"key":"2025111201300703000_34.178.250016.57","unstructured":"Ministero della salute. Italy . Vaccinations by age, category and condition. Date last accessed: December 2024. www.salute.gov.it\/portale\/vaccinazioni\/menuContenutoVaccinazioni.jsp?lingua=italiano&area=vaccinazioni&menu=fasce"},{"key":"2025111201300703000_34.178.250016.58","unstructured":"Ministrio de Salud Argentina . Reuni\u00f3n de la Comisi\u00f3n Nacional de Inmunizaci\u00f3n (CoNaIn). Date last accessed: December 2024. www.argentina.gob.ar\/sites\/default\/files\/2022\/01\/acta_conain_29122022.pdf"},{"key":"2025111201300703000_34.178.250016.59","unstructured":"Ministry of Health - Epidemiology Division . Pneumococcal vaccine. Update for adult vaccination. Israel. Date last accessed: December 2024. www.gov.il\/BlobFolder\/policy\/pneumo\/he\/files_publications_units_epidemiology_vaccine_guidelines_Pneumo-Adult-120723.pdf"},{"key":"2025111201300703000_34.178.250016.60","unstructured":"Bundesamt f\u00fcr Gesundheit BAG . Pneumokokkenimpfung neu f\u00fcr alle Personen ab dem Alter von 65 Jahren als erg\u00e4nzende Impfung empfohlen. Date last accessed: December 2024. https:\/\/www.bag.admin.ch\/dam\/de\/sd-web\/iwfmmvyvn74o\/art.12a_bst.f_Art.12a_erg\u00e4nzende_impfempfehlungen_pneumokokken_ab_alter_65j_30oktober2023.pdf"},{"key":"2025111201300703000_34.178.250016.61","unstructured":"Australian Government . Department of Health and Aged Care. Pneumococcal disease. Date last accessed: December 2024. https:\/\/immunisationhandbook.health.gov.au\/contents\/vaccine-preventable-diseases\/pneumococcal-disease#people-with-medical-risk-factors"},{"key":"2025111201300703000_34.178.250016.62","unstructured":"Joint Committee on Vaccination and Immunisation . Minute of the meeting held on 07 June 2023. Date last accessed: December 2024. https:\/\/app.box.com\/s\/iddfb4ppwkmtjusir2tc\/file\/1262409204637"},{"key":"2025111201300703000_34.178.250016.63","unstructured":"Lithuanian Society of Infectious Diseases . Adult vaccination recommendations in Lithuania. Date last accessed: December 2024. https:\/\/nvsc.lrv.lt\/uploads\/nvsc\/documents\/files\/A5-Suaugusiuju-skiepijimo-Lietuvoje-rekomendacijos_2022.pdf"},{"key":"2025111201300703000_34.178.250016.64","unstructured":"Associa\u00e7\u00e3o Portuguesa de Medicina Geral e Familiar . Recomenda\u00e7\u00f5es GRESP para a vacina\u00e7\u00e3o antipneumoc\u00f3cica na popula\u00e7\u00e3o adulta (> 18 anos) \u2013 Revis\u00e3o 2022. Date last accessed: December 2024. https:\/\/apmgf.pt\/cento_d_documentos\/recomendacoes-gresp-para-a-vacinacao-antipneumococica-na-populacao-adulta-18-anos-revisao-2022\/"},{"key":"2025111201300703000_34.178.250016.65","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12913-016-1432-4","article-title":"Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions","volume":"16","author":"Weycker","year":"2016","journal-title":"BMC Health Serv Res"},{"key":"2025111201300703000_34.178.250016.66","unstructured":"Centers for Disease Control and Prevention . Summary of risk-based pneumococcal vaccination recommendations. Date last accessed: December 2024. www.cdc.gov\/pneumococcal\/hcp\/vaccine-recommendations\/risk-indications.html"},{"key":"2025111201300703000_34.178.250016.67","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 . Strat\u00e9gie de vaccination contre les infections \u00e0 pneumocoque. Date last accessed: December 2024. www.has-sante.fr\/upload\/docs\/application\/pdf\/2023-08\/strategie_de_vaccination_contre_les_infections_a_pneumocoque_place_du_vaccin_pneumococcique_polyosidique_conjugue_20-valent_.pdf"},{"key":"2025111201300703000_34.178.250016.68","unstructured":"Servicio de Salud de Castilla-La Mancha . Other provisions and acts. Date last accessed: December 2024. https:\/\/sanidad.castillalamancha.es\/sites\/sescam.castillalamancha.es\/files\/documentos\/paginas\/archivos\/resolucion_grupos_de_riesgo_clm_2023.pdf"},{"key":"2025111201300703000_34.178.250016.69","unstructured":"Folkh\u00e4lsomyndigheten . Rekommendationer om pneumokockvaccination till riskgrupper. Date last accessed: December 2024. www.folkhalsomyndigheten.se\/publikationer-och-material\/publikationsarkiv\/r\/rekommendationer-om-pneumokockvaccination-\/?pub=56914"},{"key":"2025111201300703000_34.178.250016.70","unstructured":"Statens Serum Institut . Pneumococcal vaccination for people >18 years who are at especially increased risk of invasive pneumococcal disease. EPI-News. Date last accessed: December 2024. https:\/\/en.ssi.dk\/news\/epi-news\/2024\/no-3---2024"},{"key":"2025111201300703000_34.178.250016.71","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1016\/j.vaccine.2018.07.039","article-title":"The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: a systematic review and meta-analysis","volume":"36","author":"Van Aalst","year":"2018","journal-title":"Vaccine"},{"key":"2025111201300703000_34.178.250016.72","unstructured":"Centers for Disease Control and Prevention . Altered immunocompetence. Date last accessed: December 2024. www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/immunocompetence.html"},{"key":"2025111201300703000_34.178.250016.73","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.406"},{"key":"2025111201300703000_34.178.250016.74","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/ibd\/izac150","article-title":"New pneumococcal vaccines for prevention of invasive pneumococcal disease in adult patients with inflammatory bowel disease","volume":"29","author":"Crosby","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2025111201300703000_34.178.250016.75","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/MCG.0000000000001954","article-title":"Rapid adoption of pneumococcal 20-valent conjugate vaccination in adult patients with inflammatory bowel disease: an analysis one year after availability","volume":"58","author":"Karime","year":"2023","journal-title":"J Clin Gastroenterol"},{"key":"2025111201300703000_34.178.250016.76","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.3390\/cancers13236140","article-title":"Vaccine responses in adult hematopoietic stem cell transplant recipients: a comprehensive review","volume":"13","author":"Janssen","year":"2021","journal-title":"Cancers"},{"key":"2025111201300703000_34.178.250016.77","doi-asserted-by":"publisher","DOI":"10.1086\/420933"},{"key":"2025111201300703000_34.178.250016.78","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/QAI.0000000000002916","article-title":"Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among adults with HIV\u2013United States, 2008\u20132018","volume":"90","author":"Kobayashi","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025111201300703000_34.178.250016.79","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1200\/JCO.24.00032","article-title":"Vaccination of adults with cancer: ASCO guideline","volume":"42","author":"Kamboj","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025111201300703000_34.178.250016.80","unstructured":"European Medicines Agency . Prevenar 20 (previously Apexxnar). Date last accessed: December 2024. www.ema.europa.eu\/en\/medicines\/human\/EPAR\/prevenar-20"},{"key":"2025111201300703000_34.178.250016.81","unstructured":"Centers for Disease Control and Prevention . Use of 20-valent pneumococcal conjugate vaccine among US children: updated recommendations of the Advisory Committee on Immunization Practices \u2013 United States, 2023. Date last accessed: December 2024. https:\/\/stacks.cdc.gov\/view\/cdc\/133252"},{"key":"2025111201300703000_34.178.250016.82","doi-asserted-by":"crossref","first-page":"e1062","DOI":"10.1093\/cid\/ciac475","article-title":"Distribution of serotypes causing invasive pneumococcal disease in children from high-income countries and the impact of pediatric pneumococcal vaccination","volume":"76","author":"Grant","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025111201300703000_34.178.250016.83","doi-asserted-by":"crossref","first-page":"e2023065218","DOI":"10.1542\/peds.2023-065218","article-title":"Safety of a 4-dose 20-valent pneumococcal conjugate vaccine series in infants: a randomized trial","volume":"154","author":"Hajdu","year":"2024","journal-title":"Pediatrics"},{"key":"2025111201300703000_34.178.250016.84","unstructured":"Government of Canada . Pneumococcal vaccines: Canadian immunization guide. Date last accessed: December 2024. www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-16-pneumococcal-vaccine.html#a7"},{"key":"2025111201300703000_34.178.250016.85","unstructured":"Argentine Society of Infectology . Pneumococcal vaccination recommendation. Date last accessed: December 2024. www.sadi.org.ar\/publicaciones\/1755-recomendacion-de-vacunacion-contra-neumococo"},{"key":"2025111201300703000_34.178.250016.86","doi-asserted-by":"crossref","unstructured":"Kimberlin DW , Banerjee R , Barnett ED , et al. Immunization in preterm and low birth weight infants. In: Red Book: 2024\u20132027 Report of the Committee on Infectious Diseases, Committee on Infectious Diseases, American Academy of Pediatrics. 33rd Edn. Itasca, IL, American Academy of Pediatrics, 2024. pp. 87\u201389. https:\/\/publications.aap.org\/redbook\/book\/755\/chapter\/14074422\/Immunization-in-Preterm-and-Low-Birth-Weight","DOI":"10.1542\/9781610027373-S1_006_001"},{"key":"2025111201300703000_34.178.250016.87","unstructured":"Australian Government, Department of Health and Aged Care . Vaccination for preterm infants. Date last accessed: December 2024. https:\/\/immunisationhandbook.health.gov.au\/contents\/vaccination-for-special-risk-groups\/vaccination-for-preterm-infants"},{"key":"2025111201300703000_34.178.250016.88","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1016\/j.vaccine.2021.07.004","article-title":"A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age","volume":"39","author":"Klein","year":"2021","journal-title":"Vaccine"},{"key":"2025111201300703000_34.178.250016.89","doi-asserted-by":"crossref","first-page":"e1489","DOI":"10.1093\/cid\/ciaa1045","article-title":"Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age","volume":"73","author":"Hurley","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025111201300703000_34.178.250016.90","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.vaccine.2024.01.004","article-title":"A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults \u226560 years of age in Japan, South Korea, and Taiwan","volume":"42","author":"Haranaka","year":"2024","journal-title":"Vaccine"},{"key":"2025111201300703000_34.178.250016.91","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1080\/21645515.2020.1863177","article-title":"A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States","volume":"17","author":"Fitz-Patrick","year":"2021","journal-title":"Hum Vaccines Immunother"},{"key":"2025111201300703000_34.178.250016.92","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1016\/j.vaccine.2023.05.002","article-title":"Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults \u226565 years old","volume":"41","author":"Fitz-Patrick","year":"2023","journal-title":"Vaccine"},{"key":"2025111201300703000_34.178.250016.93","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.vaccine.2022.11.046","article-title":"Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: a phase 3 randomized trial","volume":"41","author":"Cannon","year":"2023","journal-title":"Vaccine"},{"key":"2025111201300703000_34.178.250016.94","doi-asserted-by":"crossref","first-page":"ofae220","DOI":"10.1093\/ofid\/ofae220","article-title":"Immunogenicity of current and next-generation pneumococcal conjugate vaccines in children: current challenges and upcoming opportunities","volume":"11","author":"Feemster","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2025111201300703000_34.178.250016.95","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/14760584.2024.2409662","article-title":"Pneumococcal serotypes missing prespecified efficacy threshold in immunogenicity trials: real-world evidence from national immunization programs","volume":"23","author":"Perdrizet","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"2025111201300703000_34.178.250016.96","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1016\/j.vaccine.2024.05.001","article-title":"The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England","volume":"42","author":"Danelian","year":"2024","journal-title":"Vaccine"},{"key":"2025111201300703000_34.178.250016.97","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.1016\/j.vaccine.2022.10.010","article-title":"Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly","volume":"40","author":"Hoshi","year":"2022","journal-title":"Vaccine"},{"key":"2025111201300703000_34.178.250016.98","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1016\/j.vaccine.2023.07.016","article-title":"Cost\u2013utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain","volume":"41","author":"Cantarero","year":"2023","journal-title":"Vaccine"},{"key":"2025111201300703000_34.178.250016.99","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1080\/14760584.2024.2350246","article-title":"Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan","volume":"23","author":"Nakamura","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"2025111201300703000_34.178.250016.100","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s40121-024-00972-9","article-title":"Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Argentinean adults","volume":"13","author":"Rey-Ares","year":"2024","journal-title":"Infect Dis Ther"},{"key":"2025111201300703000_34.178.250016.101","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/14760584.2023.2262575","article-title":"Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany","volume":"22","author":"K\u00fchne","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"2025111201300703000_34.178.250016.102","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1080\/14737167.2022.2134120","article-title":"Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease","volume":"22","author":"Mendes","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2025111201300703000_34.178.250016.103","doi-asserted-by":"crossref","first-page":"1229524","DOI":"10.3389\/fpubh.2023.1229524","article-title":"Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece","volume":"11","author":"Gourzoulidis","year":"2023","journal-title":"Front Public Health"},{"key":"2025111201300703000_34.178.250016.104","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1080\/14760584.2023.2273892","article-title":"Cost\u2013utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults","volume":"22","author":"Marbaix","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"2025111201300703000_34.178.250016.105","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1080\/14760584.2022.2104250","article-title":"Public health and budgetary impact of 20-valent pneumococcal conjugate vaccine for adults in England","volume":"21","author":"Mugwagwa","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"2025111201300703000_34.178.250016.106","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1080\/13696998.2022.2152235","article-title":"Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23","volume":"25","author":"Olsen","year":"2022","journal-title":"J Med Econ"},{"key":"2025111201300703000_34.178.250016.107","unstructured":"Government of Canada . Recommendations on the use of conjugate pneumococcal vaccine - 15 valent (PNEU-C-15) and 20 valent (PNEU-C-20) in adults: economic evidence supplementary appendix. Date last accessed: December 2024. www.canada.ca\/en\/public-health\/services\/immunization\/national-advisory-committee-on-immunization-naci\/public-health-level-recommendations-use-pneumococcal-vaccines-adults-including-use-15-valent-20-valent-conjugate-vaccines\/economic-evidence-supplementary-appendix.html#a2"},{"key":"2025111201300703000_34.178.250016.108","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.3390\/vaccines10122032","article-title":"Cost-effectiveness of vaccination with the 20-valent pneumococcal conjugate vaccine in the Italian adult population","volume":"10","author":"Polistena","year":"2022","journal-title":"Vaccines"},{"key":"2025111201300703000_34.178.250016.109","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3390\/vaccines11071253","article-title":"Cost-effectiveness of pneumococcal vaccination in adults in Italy: comparing new alternatives and exploring the role of GMT ratios in informing vaccine effectiveness","volume":"11","author":"Restivo","year":"2023","journal-title":"Vaccines"},{"key":"2025111201300703000_34.178.250016.110","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.1016\/j.vaccine.2022.10.066","article-title":"Cost-effectiveness of revised US pneumococcal vaccination recommendations in underserved minority adults <65-years-old","volume":"40","author":"Wateska","year":"2022","journal-title":"Vaccine"},{"key":"2025111201300703000_34.178.250016.111","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12916-024-03277-3","article-title":"Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands","volume":"22","author":"de Boer","year":"2024","journal-title":"BMC Med"},{"key":"2025111201300703000_34.178.250016.112","first-page":"238146832311744","article-title":"Evolution of pneumococcal vaccine recommendations and criteria for decision making in 5 western European countries and the United States","volume":"8","author":"Noharet-Koenig","year":"2023","journal-title":"MDM Policy Pract"},{"key":"2025111201300703000_34.178.250016.113","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1111\/jgs.19031","article-title":"Changes in the cost-effectiveness of pneumococcal vaccination and of programs to increase its uptake in US older adults","volume":"72","author":"Wateska","year":"2024","journal-title":"J Am Geriatr Soc"},{"key":"2025111201300703000_34.178.250016.114","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa535"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0016-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T09:30:26Z","timestamp":1762939826000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0016-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":114,"journal-issue":{"issue":"178","published-online":{"date-parts":[[2025,11,12]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1183\/16000617.0016-2025"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0016-2025","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}